Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2274265 | 0.99 | DHODH (0.49) | DHODHACMSDHCRTR1HCRTR2CYP11B1 | |
| SCHEMBL2279807 | 0.87 | HCRTR2 (0.45) | DHODHHCRTR1HCRTR2CYP11B1CYP11B2 | |
| SCHEMBL8073486 | 0.81 | HCRTR2 (0.46) | DHODHHCRTR1HCRTR2CSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL2282906 | 0.81 | HCRTR2 (0.45) | DHODHHCRTR1HCRTR2CSNK2A2CSNK2B | |
| SCHEMBL12373309 | 0.76 | HCRTR2 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL2279413 | 0.75 | HCRTR2 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL13778292 | 0.75 | CYP11B1 (0.51) | CYP11B1CYP11B2CTSA | |
| SCHEMBL2253822 | 0.74 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL29058647 | 0.72 | NPC1 (0.48) | DHODHACMSDCSNK2A2CSNK2B | |
| SCHEMBL30394985 | 0.72 | NPC1 (0.48) | DHODHACMSDCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003797-B2 | Pyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | DHODH 1708/4885ACMSD 3474/4885HCRTR1 2/4885 |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY1R | DHODH 1708/4885ACMSD 3474/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.